Erasca Inc
NASDAQ:ERAS
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1.67
3.28
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
Abbvie Inc
NYSE:ABBV
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Realty Income Corp
NYSE:O
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ERAS stock under the Base Case scenario is 1.18 USD. Compared to the current market price of 2.97 USD, Erasca Inc is Overvalued by 60%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Erasca Inc
Run backtest to discover the historical profit from buying and selling ERAS based on its intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Price Target |
Loading
|
Revenue Forecast |
|
Operating Income Forecast |
|
Earnings Forecast |
|
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Erasca Inc
Balance Sheet Decomposition
Erasca Inc
Current Assets | 418m |
Cash & Short-Term Investments | 408.4m |
Other Current Assets | 9.6m |
Non-Current Assets | 107.7m |
Long-Term Investments | 51.8m |
PP&E | 51.5m |
Other Non-Current Assets | 4.4m |
Current Liabilities | 24.9m |
Accounts Payable | 2.1m |
Accrued Liabilities | 22.6m |
Other Current Liabilities | 155k |
Non-Current Liabilities | 49.8m |
Other Non-Current Liabilities | 49.8m |
Earnings Waterfall
Erasca Inc
Revenue
|
0
USD
|
Operating Expenses
|
-148m
USD
|
Operating Income
|
-148m
USD
|
Other Expenses
|
-10.3m
USD
|
Net Income
|
-158.3m
USD
|
Free Cash Flow Analysis
Erasca Inc
USD | |
Free Cash Flow | USD |
ERAS Profitability Score
Profitability Due Diligence
Erasca Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
Score
Erasca Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
ERAS Solvency Score
Solvency Due Diligence
Erasca Inc's solvency score is 70/100. The higher the solvency score, the more solvent the company is.
Score
Erasca Inc's solvency score is 70/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ERAS Price Targets Summary
Erasca Inc
According to Wall Street analysts, the average 1-year price target for ERAS is 4.66 USD with a low forecast of 3.03 USD and a high forecast of 7.35 USD.
Shareholder Yield
Current shareholder yield for ERAS is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
ERAS Price
Erasca Inc
Average Annual Return | -37.87% |
Standard Deviation of Annual Returns | 48.95% |
Max Drawdown | -93% |
Market Capitalization | 802.7m USD |
Shares Outstanding | 272 817 984 |
Percentage of Shares Shorted | 9.13% |
Ownership
ERAS Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Erasca, Inc. is a clinical stage precision oncology company that focuses on discovering, developing, and commercializing therapies for RAS/MAPK pathway-driven cancers. The company is headquartered in San Diego, California and currently employs 123 full-time employees. The company went IPO on 2021-07-15. The firm is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The firm is engaged in oncology and RAS targeting to create therapies and combination regimens for the treatment of cancer. Its product candidates are ERAS-007 and ERAS-601, which together comprises its MAPKlamp. In addition, it also includes two discovery programs, ERAS-9 and ERAS-11, small molecule inhibitor programs targeting SOS1 and MYC, respectively. Its MAPKlamp is an approach targeting upstream and downstream nodes in the RAS/MAPK pathway designed to shut down, or clamp, the signaling of various oncogenic drivers, such as RTKs, NF1, RAS, RAF, and MEK alterations trapped in between any nodes involving this pathway. With its MAPKlamp approach, it induces tumor regression in RAS/MAPK pathway-driven cancers, while also blocking the escape routes that lead to tumor resistance.
Contact
IPO
Employees
Officers
The intrinsic value of one ERAS stock under the Base Case scenario is 1.18 USD.
Compared to the current market price of 2.97 USD, Erasca Inc is Overvalued by 60%.